Prices are updated after-hours


Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

published : This week    tags : Treatment    save search

Progressive Familial Intrahepatic Cholestasis Treatment Market Projected to Reach $156.14 million by 2030 - Exclusive Report by 360iResearch
Published: 2024-04-19 (Crawled : 02:00) - prnewswire.com
SNY | News | $45.395 -1.55% -1.58% 4.4M twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist
SNYNF | News | $92.7 -2.18% 1.4K twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist
TAK | News | $13.16 0.08% 0.0% 1.3M twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist
MIRM | $23.6 -1.05% -1.06% 400K twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist

report million reach treatment market
California Water Service Group Moving Forward to Install PFAS Treatment Despite CPUC Dismissal of Request to Track Capital Costs in Pre-Approved Memorandum Account
Published: 2024-04-18 (Crawled : 21:00) - globenewswire.com
CWT | News | $44.9 1.65% 0.0% 340K twitter stocktwits trandingview |
Utilities
| Email alert Add to watchlist

water california service group treatment
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
Published: 2024-04-18 (Crawled : 19:00) - biospace.com/
MBRX | News | $4.59 7.24% 6.75% 50K twitter stocktwits trandingview |
Health Technology
| | O: 4.91% H: 11.36% C: 0.67%

drug treatment designation for grants leukemia
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Published: 2024-04-18 (Crawled : 13:00) - globenewswire.com
ONCT | News | $8.79 -1.79% -1.82% 2.8K twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist

onct-534 first cancer treatment for study
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
Published: 2024-04-17 (Crawled : 22:00) - biospace.com/
DMAC | $2.45 -5.77% -6.12% 17K twitter stocktwits trandingview |
Health Technology
| | O: 4.43% H: 0.0% C: 0.0%

dm199 first stroke treatment for trial therapeutics
ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
Published: 2024-04-17 (Crawled : 13:00) - globenewswire.com
ABVC | News | $0.9963 -2.32% -2.38% 460K twitter stocktwits trandingview |
Wholesale Trade
| | O: 2.68% H: 3.48% C: -11.3%

treatment biopharma royalties global for agreement
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
Published: 2024-04-17 (Crawled : 12:00) - prnewswire.com
NRBO | $3.425 -1.01% -1.02% 23K twitter stocktwits trandingview |
Health Technology
| | O: 8.53% H: 0.0% C: -6.23%

da-1726 obesity first treatment pharmaceuticals for trial
New Precision Oncology Tests to Drive Personalised Therapies and Improved Treatment Outcomes
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
GENE | News 0 d | $2.36 -25.32% -33.9% 88K twitter stocktwits trandingview |
Health Technology
| | O: 3.47% H: 0.0% C: -3.66%

precision treatment
Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
CMND | $1.2 0.84% 0.83% 35K twitter stocktwits trandingview |
n/a
| | O: -0.82% H: 0.0% C: 0.0%

disorders treatment for agreement
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
Published: 2024-04-17 (Crawled : 12:00) - biospace.com/
SAGE | $13.03 3.66% 3.53% 1.8M twitter stocktwits trandingview |
Health Technology
| | O: -15.02% H: 3.55% C: -3.01%

sage-718 disease treatment topline parkinson’s therapeutics results study
Prostate Cancer: Advancements in Prevention and Treatment Drive Global Market Growth
Published: 2024-04-17 (Crawled : 09:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K twitter stocktwits trandingview |
Health Technology
| | O: 0.12% H: 0.51% C: 0.51%
JNJ | News | $145.74 0.67% 0.0% 9.3M twitter stocktwits trandingview |
Health Technology
| | O: -0.04% H: 0.28% C: -0.16%
SNY | News | $45.395 -1.55% -1.58% 4.4M twitter stocktwits trandingview |
Health Technology
| | O: 1.05% H: 0.0% C: 0.0%

treatment global growth market
Fracking Water Treatment Market size to record USD 1.20 billion growth from 2023-2027, Adoption of supercritical carbon in fracking is one of the key market trends, Technavio
Published: 2024-04-16 (Crawled : 23:00) - prnewswire.com
XYL | $127.16 0.75% 0.0% 1.1M twitter stocktwits trandingview |
Producer Manufacturing
| | O: 0.38% H: 0.0% C: -1.77%

water one treatment key growth market
Evidence for Clene’s CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting
Published: 2024-04-16 (Crawled : 20:00) - globenewswire.com
CLNN S | $0.3275 -3.56% -3.69% 1.2M twitter stocktwits trandingview |
| Email alert Add to watchlist

au8 neurology sclerosis treatment for meeting
Sentynl Therapeutics Receives MHRA Authorization of NULIBRY® (fosdenopterin) for Treatment of MoCD Type A in Great Britain
Published: 2024-04-16 (Crawled : 16:00) - biospace.com/
BBIO | $24.98 0.0% 2M twitter stocktwits trandingview |
Health Technology
| | O: -1.47% H: 2.05% C: -0.59%

nulibry authorization treatment for therapeutics
Emphysema Treatment Market to Reach $8.7 Billion, Globally, by 2032 at 3.3% CAGR: Allied Market Research
Published: 2024-04-16 (Crawled : 14:00) - prnewswire.com
VTRS | $11.11 0.09% 0.09% 3.5M twitter stocktwits trandingview |
Health Technology
| | O: -0.53% H: 0.0% C: -1.24%
NVS | $92.57 -0.55% 0.0% 910K twitter stocktwits trandingview |
Health Technology
| | O: -1.46% H: 0.0% C: 0.0%
PHG | $19.98 -0.84% 0.0% 500K twitter stocktwits trandingview |
Health Technology
| | O: -1.21% H: 0.0% C: 0.0%
GSK | $39.27 -0.83% 0.01% 2.2M twitter stocktwits trandingview |
Health Technology
| | O: -1.19% H: 0.52% C: -0.17%
VRNA | $16.1 -1.83% -1.86% 490K twitter stocktwits trandingview |
Health Technology
| | O: 1.65% H: 2.43% C: 0.87%

reach treatment research market
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy
Published: 2024-04-16 (Crawled : 12:00) - globenewswire.com
LXEO | $12.1 -1.31% -1.32% 83K twitter stocktwits trandingview |
| | O: 5.32% H: 0.0% C: -2.63%

lx2006 fda candidate granted treatment designation for therapeutics therapy
Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting
Published: 2024-04-15 (Crawled : 21:00) - globenewswire.com
ZVRA | $4.51 -2.8% -2.88% 260K twitter stocktwits trandingview |
n/a
| | O: 1.15% H: 1.03% C: -1.45%

disease treatment for meeting therapeutics
Robbins Geller Rudman & Dowd LLP, Lieff Cabraser Heimann & Bernstein LLP, and Dugan Law Firm, APLC Announce a $78 Million Class Action Settlement for Third Party Payors That Paid or Reimbursed Costs for Prescription Opioids or Treatment Related to Opioid Misuse, Addiction, and/or Overdose
Published: 2024-04-15 (Crawled : 20:00) - prnewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M twitter stocktwits trandingview |
Health Technology
| | O: -2.09% H: 0.0% C: 0.0%

opioid million treatment for
Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea & Vomiting at the Upcoming ASPAN 2024 National Conference in Orlando, Florida
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
EGRX | $4.505 2.62% 2.55% 140K twitter stocktwits trandingview |
Health Technology
| | O: -8.14% H: 19.55% C: 18.18%

conference treatment pharmaceuticals for trial response
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
Published: 2024-04-15 (Crawled : 11:00) - globenewswire.com
RARE F | $43.38 -1.65% -1.68% 770K twitter stocktwits trandingview |
Health Technology
| | O: -10.79% H: 0.0% C: -3.75%

gtx-102 positive treatment
Gainers vs Losers
64% 36%

Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M twitter stocktwits trandingview |
Finance

ZCMD | $2.86 108.76% 52.1% 2.3M twitter stocktwits trandingview |
Commercial Services

INVO | $1.555 104.6% 51.13% 5M twitter stocktwits trandingview |
Health Technology

ISPC | $0.437 105.16% 49.53% 37M twitter stocktwits trandingview |
Professional, Scientific, and T...

WLGS | News | $0.92 84.0% 45.65% 1.6M twitter stocktwits trandingview |

OST | $0.499 21.38% 45.26% 1.9M twitter stocktwits trandingview |

XPON | News | $3.1 60.62% 37.74% 17M twitter stocktwits trandingview |

TIRX | $0.7 44.39% 30.74% 58M twitter stocktwits trandingview |

BNTC | News | $6.92 44.17% 30.64% 3.5M twitter stocktwits trandingview |
Health Technology

GGE | $0.035 19.86% 29.3% 64M twitter stocktwits trandingview |


Your saved searches
Save your searches and get alerts when important news are released.